DAIC

FEBRUARY 29, 2024

Clinical and Investigative Horizons (Session 410) Sunday, April 7 4:30 – 5:45 p.m.

Aortic valve 103

Aortic valve Myocardial Infarction Aortic Blood Pressure 103

Cardiology Update

APRIL 9, 2024

Investigators assessed if empagliflozin could lower the risk of hospitalization for heart failure (HF) or death from cardiovascular disease (CVD). STEP-HFpEF DM 5 ( NCT04916470 ) explored the effects of semaglutide in obesity-related HF with preserved ejection fraction (HFpEF) and type 2 diabetes.

Angina 52

Angina Myocardial Infarction Aortic valve Coronary Artery Disease 52

Cardiometabolic Health Congress

NOVEMBER 14, 2024

Cardiovascular disease remains the leading cause of death worldwide , claiming 18 million lives annually. 42% of adults are considered obese , increasing their risk of diabetes, hypertension, and cardiovascular issues. Moreover, cardiovascular disease in women continues to be underrepresented and undertreated.

CME 103

CME Obesity Heart Failure Biomarkers 103

Cardiometabolic Health Congress

NOVEMBER 22, 2024

Heart Failure Management : The FINEARTS-HF trial focused on the efficacy of finerenone, an aldosterone antagonist, in reducing heart failure hospitalizations and cardiovascular mortality among patients with preserved ejection fraction (HFpEF).

Blood Pressure 59

Blood Pressure Obesity Preserved Ejection Fraction Coronary Artery Disease 59